{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:46:44Z","timestamp":1778932004061,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013105","name":"Shanghai Rising-Star Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013105","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.yexcr.2019.111800","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T12:47:58Z","timestamp":1577105278000},"page":"111800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Felodipine blocks osteoclast differentiation and ameliorates estrogen-dependent bone loss in mice by modulating p38 signaling pathway"],"prefix":"10.1016","volume":"387","author":[{"given":"Shutao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haozheng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shicheng","family":"Huo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin'en","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2019.111800_bib1","doi-asserted-by":"crossref","first-page":"16069","DOI":"10.1038\/nrdp.2016.69","article-title":"Postmenopausal osteoporosis","volume":"2","author":"Eastell","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.yexcr.2019.111800_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2019.111800_bib3","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.yexcr.2019.111800_bib4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2019.111800_bib5","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1056\/NEJM199803123381107","article-title":"Treatment of postmenopausal osteoporosis","volume":"338","author":"Eastell","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2019.111800_bib6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.yexcr.2019.111800_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2019.111800_bib8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMcp043801","article-title":"Clinical practice. Postmenopausal osteoporosis","volume":"353","author":"Rosen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2019.111800_bib9","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0301-472X(99)00061-2","article-title":"Cell biology of the osteoclast","volume":"27","author":"Roodman","year":"1999","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.yexcr.2019.111800_bib10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2019.111800_bib11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrg1122","article-title":"Genetic regulation of osteoclast development and function","volume":"4","author":"Teitelbaum","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.yexcr.2019.111800_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.molmed.2005.11.007","article-title":"RANKL-RANK signaling in osteoclastogenesis and bone disease","volume":"12","author":"Wada","year":"2006","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.yexcr.2019.111800_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH645>3.0.CO;2-Q","article-title":"Regulation of the differentiation and function of osteoclasts","volume":"192","author":"Chambers","year":"2000","journal-title":"J. Pathol."},{"key":"10.1016\/j.yexcr.2019.111800_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103004","article-title":"Roles of mitogen-activated protein kinases in osteoclast biology","volume":"19","author":"Lee","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexcr.2019.111800_bib15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.7150\/ijbs.13814","article-title":"Selective regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation","volume":"12","author":"Lee","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.yexcr.2019.111800_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0006-291X(03)00695-8","article-title":"Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts","volume":"305","author":"Lee","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.yexcr.2019.111800_bib17","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1210\/me.2007-0237","article-title":"NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP)","volume":"22","author":"Kim","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.yexcr.2019.111800_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.11005\/jbm.2014.21.4.233","article-title":"Regulation of NFATc1 in osteoclast differentiation","volume":"21","author":"Kim","year":"2014","journal-title":"J Bone Metab"},{"key":"10.1016\/j.yexcr.2019.111800_bib19","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.yexcr.2019.111800_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00223-012-9671-9","article-title":"The relationship among hypertension, antihypertensive medications, and osteoporosis: a narrative review","volume":"92","author":"Ilic","year":"2013","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.yexcr.2019.111800_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00198-013-2457-8","article-title":"Association between hypertension and fragility fracture: a longitudinal study","volume":"25","author":"Yang","year":"2014","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.yexcr.2019.111800_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-008-9198-2","article-title":"Hypertension is a risk factor for fractures","volume":"84","author":"Vestergaard","year":"2009","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.yexcr.2019.111800_bib23","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJM199911043411907","article-title":"Calcium-antagonist drugs","volume":"341","author":"Abernethy","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexcr.2019.111800_bib24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12877-015-0154-5","article-title":"Risk of hip fracture among older people using antihypertensive drugs: a nationwide cohort study","volume":"15","author":"Ruths","year":"2015","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.yexcr.2019.111800_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/01.hjh.0000203845.26690.cb","article-title":"Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study","volume":"24","author":"Rejnmark","year":"2006","journal-title":"J. Hypertens."},{"key":"10.1016\/j.yexcr.2019.111800_bib26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00003495-199244020-00008","article-title":"Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders","volume":"44","author":"Todd","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.yexcr.2019.111800_bib27","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.biopha.2018.10.052","article-title":"DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo","volume":"109","author":"Ishida","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.yexcr.2019.111800_bib28","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jbmr.3334","article-title":"A novel diterpenoid suppresses osteoclastogenesis and promotes osteogenesis by inhibiting ifrd1-mediated and IkappaBalpha-mediated p65 nuclear translocation","volume":"33","author":"Xie","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.yexcr.2019.111800_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.yexcr.2014.07.005","article-title":"Geraniin suppresses RANKL-induced osteoclastogenesis in vitro and ameliorates wear particle-induced osteolysis in mouse model","volume":"330","author":"Xiao","year":"2015","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.yexcr.2019.111800_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.yexcr.2019.111800_bib31","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.clinthera.2015.06.006","article-title":"The pathophysiology and treatment of osteoporosis","volume":"37","author":"Drake","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.yexcr.2019.111800_bib32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.2016.11032","article-title":"Osteoporosis therapy in postmenopausal women with high risk of fracture","volume":"316","author":"Cappola","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.yexcr.2019.111800_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.yexcr.2019.111800_bib34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","article-title":"Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States","volume":"90","author":"Singer","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.yexcr.2019.111800_bib35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.yexcr.2019.111800_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2008.09.012","article-title":"Osteonecrosis of the jaw: who gets it, and why?","volume":"44","author":"Reid","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.yexcr.2019.111800_bib37","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.yexcr.2019.111800_bib38","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.yexcr.2019.111800_bib39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00774-012-0389-6","article-title":"Fracture risk is increased by the complication of hypertension and treatment with calcium channel blockers in postmenopausal women with type 2 diabetes","volume":"31","author":"Takaoka","year":"2013","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.yexcr.2019.111800_bib40","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1001\/2013.jamainternmed.469","article-title":"The risk of hip fracture after initiating antihypertensive drugs in the elderly","volume":"172","author":"Butt","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.yexcr.2019.111800_bib41","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00198-013-2369-7","article-title":"The risk of falls on initiation of antihypertensive drugs in the elderly","volume":"24","author":"Butt","year":"2013","journal-title":"Osteoporos. Int."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482719306883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482719306883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:27:30Z","timestamp":1757996850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482719306883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0014482719306883"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2019.111800","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Felodipine blocks osteoclast differentiation and ameliorates estrogen-dependent bone loss in mice by modulating p38 signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2019.111800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111800"}}